$1,000 Invested in Eli Lilly 5 Years Ago Is Now Worth Over $5,000. Could It Soar That Much Again by 2031?
The pharma giant offers investors a mix of safety and growth.
Investing $1,000 in Eli Lilly five years ago would now yield over $5,000, and the company's growth potential could continue into 2031. Lilly specializes in treatments, particularly in the weight loss drug sector where it has seen impressive double-digit revenue growth. Their GLP-1 drugs, Mounjaro and Zepbound, have proven effective and are self-administered, leading to increased demand.
Despite not being the original leader in GLP-1 drugs, Lilly has surged ahead, and a recent earnings report highlights the power of its weight loss portfolio, with Mounjaro and Zepbound driving significant revenue growth. The company also boasts a robust pipeline of weight loss drug candidates, including a promising pill, Retatrutide, in phase 3 trials.
With a potential gain of around 420%, Lilly's share price could rise to $7,092 and its market cap to $6.3 trillion, surpassing the value of major technology leaders. While other sectors may also experience growth, Lilly's unique position and potential for gains make it an attractive investment option.
Rewritten by urgent.news; may contain errors — check the original.
Source: fool.com